Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Strong Buy

Price to Earnings Rating

Strong Buy

Analyst Rating

Buy

Simple Moving Average

Buy

Exponential Moving Average

Strong Buy

Relative Strength Index

Neutral

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Strong Sell

Wall Street Data Solutions Rating

Buy

A

AnaptysBio, Inc. Common Stock (ANAB)

Pharmaceutical Preparations

https://www.anaptysbio.com

AnaptysBio Inc is a clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product candidates are ANB020, ANB019, and Checkpoint receptor agonists. The entity generates revenue from collaborative research and development arrangements.

10770 WATERIDGE CIRCLE, SUITE 210
SAN DIEGO, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

01/26/2017

Market Cap

955,784,626

Shares Outstanding

26,580,000

Weighted SO

26,575,178

Total Employees

N/A

Upcoming Earnings

08/05/2024

Similar Tickers

DCPH --.--%

CRNX --.--%

RYTM --.--%

KURA --.--%

CTMX --.--%

Beta

-0.2410

Last Div

0.0000

Range

13.36-41.308

Chg

2.3700

Avg Vol

344217

Mkt Cap

955784626

Exch

NASDAQ

Country

US

Phone

858 362 6295

DCF Diff

56.3214

DCF

-21.5714

Div Yield

0.0000

P/S

31.3650

EV Multiple

-8.4047

P/FV

96.4203

Div Yield %

0.0000

P/E

-5.5994

PEG

-0.3328

Payout

0.0000

Current Ratio

9.0883

Quick Ratio

9.0883

Cash Ratio

1.7769

DSO

107.8842

DIO

0.0002

Op Cycle

107.8843

DPO

744.9290

CCC

-637.0447

Gross Margin

0.9214

Op Margin

-5.3289

Pretax Margin

-5.5823

Net Margin

-5.5825

Eff Tax Rate

-0.0581

ROA

-0.3980

ROE

-2.5567

ROCE

-0.4197

NI/EBT

1.0000

EBT/EBIT

1.0475

EBIT/Rev

-5.3289

Debt Ratio

0.8513

D/E

36.8287

LT Debt/Cap

0.9734

Total Debt/Cap

0.9736

Int Coverage

-34.1656

CF/Debt

-0.3557

Equity Multi

43.2611

Rec Turnover

3.3833

Pay Turnover

0.4900

Inv Turnover

999999.9999

FA Turnover

1.7795

Asset Turnover

0.0713

OCF/Share

-4.7302

FCF/Share

-4.7485

Cash/Share

12.8237

OCF/Sales

-4.2463

FCF/OCF

1.0039

CF Coverage

-0.3557

ST Coverage

-69.9449

CapEx Coverage

-257.7649

Div&CapEx Cov

-257.7649

P/BV

96.4203

P/B

96.4203

P/S

31.3650

P/E

-5.5994

P/FCF

-7.3578

P/OCF

-7.3613

P/CF

-7.3613

PEG

-0.3328

P/S

31.3650

EV Multiple

-8.4047

P/FV

96.4203

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Feb 29, 14:15 Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting GlobeNewswire Inc. Feb 29, 14:15 Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting GlobeNewswire Inc. Nov 27, 16:15 Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals Zacks Investment Research Nov 24, 12:29 Atara Biotherapeutics (ATRA) Slumps 57% in a Month: Here's Why GlobeNewswire Inc. Nov 01, 09:15 Anaptys Announces Participation in November Investor Conferences

Revenue Product Segmentation